Kymera Therapeutics, Inc. announced its research and development goals and key milestones for 2022. 2022 Pipeline Objectives: Kymera is discovering and developing novel small molecule therapeutics designed to selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system, with an initial focus on immune-inflammatory diseases and oncology. MDM2 Degrader Program: At last month's R&D Day, Kymera announced its new development program and development candidate, KT-253, a potent and selective degrader of MDM2 with potential to be a best-in-class P53 stabilizer.

Degradation of MDM2, rather than inhibition, has the ability to block the feedback loop which up-regulates MDM2 production and in doing so more effectively drives tumor cells to rapid apoptosis. KT-253 inhibits tumor cell growth with picomolar potency that is more than 200-fold greater than clinically active MDM2 small molecule inhibitors. This leads to sustained tumor regression in vivo in leukemia models following just a single dose.

As wild-type p53 is present in >50% of tumors, KT-253 represents another program with broad franchise potential in liquid and solid tumors. Kymera is focused on indications with specific sensitivity to this mechanism of action, such as AML, lymphomas, uveal melanoma and others through a focused biomarker strategy. Expected 2022 Milestones: Present additional preclinical data that outline the biomarker strategy as well as new indications for KT-253.

File IND for KT-253. Discovery and Platform: Kymera is also actively advancing a broad pipeline of preclinical programs across a wide variety of diseases, both internally and in collaboration with existing partners Vertex Pharmaceuticals and Sanofi. The internal programs continue to be focused on undrugged or inadequately drugged nodes within highly validated pathways.

Kymera is committed to drugging all high value target classes in human cells in a technology- and disease-agnostic manner with particular focus on using tissue-selective or -restricted E3 ligase and molecular glue degraders where needed to elicit the best clinical response. Key 2022 Objectives: Nominate first Development Candidate using a tissue restricted E3 ligase. Continue pipeline expansion by advancing early-stage discovery programs toward IND-enabling studies.

Further expand the capabilities of Kymera's Pegasus™ platform to identify the optimal pairing of disease-causing protein targets with E3 ligases to generate novel degrader product candidates. Leverage Kymera's E3 Ligase Whole-Body Atlas of over 600 unique E3 ligases to identify previously unliganded E3 ligases, including tissue-restricted or -selective, as well as new small molecule molecular glue degraders to unlock new opportunities across broad therapeutic applications. 2022 Corporate Objectives: Kymera's mission is to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation.

The Company's goal is to become a fully integrated biopharmaceutical company with a pipeline of novel medicines targeting disease-causing proteins that were previously intractable. In 2022, Kymera plans to continue to grow and strengthen its organizational capabilities in order to deliver on the potential of inventing a new class of protein degrader medicines for patients. Key Objectives: Continue to foster company culture of transparency, inclusion, communication, problem solving, and innovation.

Scale organization with continued growth in key functional areas, including clinical development, manufacturing, drug discovery, preclinical development, and G&A functions to support Kymera's growth. Continue to advance existing collaborations, or execute additional strategic partnerships that can contribute complementary capabilities in disease areas both within and outside of Kymera's core areas of therapeutic focus to further extend the potential impact of protein degrader therapies to even more patients and diseases.